<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="2021-03">2021-03</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Grace</forename><forename type="middle">Lai‐hung</forename><surname>Wong</surname></persName>
							<idno type="ORCID">0000-0002-2863-9389</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> Department of Medicine and Therapeutics,</note>
								<orgName type="department">Department of Medicine and Therapeutics</orgName>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>†</label> Medical Data Analytic Centre (MDAC),</note>
								<orgName type="laboratory">Medical Data Analytic Centre (MDAC)</orgName>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>‡</label> Institute of Digestive Disease,</note>
								<orgName type="department">Institute of Digestive Disease</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pong‐chi</forename><surname>Yuen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andy</forename><forename type="middle">Jinhua</forename><surname>Ma</surname></persName>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>§</label> Department of Computer Science, Hong Kong Baptist University, Kowloon Tong, Hong Kong</note>
								<orgName type="department">Department of Computer Science</orgName>
								<orgName type="institution">Hong Kong Baptist University</orgName>
								<address>
									<settlement>Kowloon Tong, Hong Kong</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anthony</forename><forename type="middle">Wing‐hung</forename><surname>Chan</surname></persName>
							<idno type="ORCID">0000-0002-1771-163X</idno>
						</author>
						<author>
							<persName><forename type="first">Howard</forename><forename type="middle">Ho‐wai</forename><surname>Leung</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vincent</forename><forename type="middle">Wai‐sun</forename><surname>Wong</surname></persName>
							<idno type="ORCID">0000-0003-2215-9410</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>*</label> Department of Medicine and Therapeutics,</note>
								<orgName type="department">Department of Medicine and Therapeutics</orgName>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>†</label> Medical Data Analytic Centre (MDAC),</note>
								<orgName type="laboratory">Medical Data Analytic Centre (MDAC)</orgName>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>‡</label> Institute of Digestive Disease,</note>
								<orgName type="department">Institute of Digestive Disease</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9/F Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong.</note>
								<orgName type="department">Department of Medicine and Therapeutics</orgName>
								<orgName type="institution">The Chinese University of Hong Kong</orgName>
								<address>
									<addrLine>9/F Prince of Wales Hospital, 30-32 Ngan Shing Street</addrLine>
									<settlement>Shatin, Hong Kong</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Department of Computer Science, Hong Kong Baptist University, Room R702, Sir Run Shaw Building, Kowloon Tong, Hong Kong.</note>
								<orgName type="department" key="dep1">Department of Computer Science</orgName>
								<orgName type="department" key="dep2">Sir Run Shaw Building</orgName>
								<orgName type="institution">Hong Kong Baptist University</orgName>
								<address>
									<postCode>R702</postCode>
									<settlement>Room, Kowloon Tong, Hong Kong</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Journal of Gastroenterology and Hepatology</title>
						<title level="j" type="abbrev">Journal of Gastroenterology and Hepatology</title>
						<idno type="ISSN">0815-9319</idno>
						<idno type="eISSN">1440-1746</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">36</biblScope>
							<biblScope unit="issue">3</biblScope>
							<biblScope unit="page" from="543" to="550"/>
							<date type="published" when="2021-03" />
						</imprint>
					</monogr>
					<idno type="MD5">1B478D9D855C2201AA1F21C92AC5A5C5</idno>
					<idno type="DOI">10.1111/jgh.15385</idno>
					<note type="submission">Accepted for publication 20 December 2020.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.3-SNAPSHOT" ident="GROBID" when="2023-02-13T23:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cirrhosis</term>
					<term>Liver fibrosis</term>
					<term>Machine learning</term>
					<term>Non-alcoholic steatohepatitis (NASH)</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Artificial intelligence (AI) has become increasingly widespread in our daily lives, including healthcare applications.</s><s>AI has brought many new insights into better ways we care for our patients with chronic liver disease, including non-alcoholic fatty liver disease and liver fibrosis.</s><s>There are multiple ways to apply the AI technology on top of the conventional invasive (liver biopsy) and noninvasive (transient elastography, serum biomarkers, or clinical prediction models) approaches.</s><s>In this review article, we discuss the principles of applying AI on electronic health records, liver biopsy, and liver images.</s><s>A few common AI approaches include logistic regression, decision tree, random forest, and XGBoost for data at a single time stamp, recurrent neural networks for sequential data, and deep neural networks for histology and images.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide and affects at least 25% of the global adult population. <ref type="bibr" target="#b0">1</ref> An updated systematic review suggests that the prevalence of NAFLD in Asia has reached 33.9% in 2012-2017. <ref type="bibr" target="#b1">2</ref></s><s>In Western countries, NAFLD and its active form non-alcoholic steatohepatitis (NASH) have become one of the leading indications for liver transplantation and an important cause of hepatocellular carcinoma. <ref type="bibr" target="#b2">3</ref></s><s>espite the importance of NAFLD at the population level, only a small proportion of patients would eventually suffer from cirrhotic complications and die from liver disease. <ref type="bibr" target="#b3">4</ref></s><s>In NAFLD patients at low risk of developing liver-related morbidity and mortality, it is doubtful if liver-specific treatments are warranted.</s><s>It is therefore important to identify high-risk patients and utilize healthcare resources wisely.</s></p><p><s>In patients with NAFLD, the presence of type 2 diabetes and the degree of liver fibrosis have the strongest correlation with adverse hepatic outcomes. <ref type="bibr" target="#b4">5</ref></s><s>Although cardiovascular disease is the most common cause of death in NAFLD, a multicenter study of patients with biopsy-proven NAFLD suggests that cirrhotic complications, hepatocellular carcinoma, and liver failure are the leading cause of death in those with advanced liver fibrosis and cirrhosis. <ref type="bibr" target="#b5">6</ref></s><s>herefore, all phase 3 clinical trials for NASH rightfully focus on patients with at least stage 2 fibrosis. <ref type="bibr" target="#b6">7</ref></s><s>It is also expected that this would be the target treatment population when a drug for NASH becomes available.</s></p><p><s>Current methods to assess NAFLD and liver fibrosis have various limitations.</s><s>There is thus much interest in improving assessments using artificial intelligence (AI).</s><s>Currently, the US Food and Drug Administration Biomarkers, EndpointS and other Tools (BEST) puts biomarkers into different categories, all of which AI may have valuable contributions (Table <ref type="table" target="#tab_0">1</ref>).</s><s>In this article, we discuss the principles of AI as it is applied in NAFLD and highlight some initial developments in this exciting field.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Current methods to assess non-alcoholic fatty liver disease and liver fibrosis</head><p><s>In routine practice, the diagnosis of NAFLD is usually based on radiological detection of fatty liver (mostly by abdominal ultrasonography) and the exclusion of excessive alcohol consumption, secondary causes of fatty liver, and concomitant liver diseases. <ref type="bibr" target="#b7">8</ref></s><s>oninvasive tests or liver biopsy are then performed to assess the severity of liver disease.</s><s>Details of noninvasive tests of NAFLD and liver fibrosis have been reviewed extensively elsewhere and are beyond the scope of this review. <ref type="bibr" target="#b8">9</ref></s><s>Suffice it to say, among noninvasive tests of fibrosis, specific fibrosis biomarkers (e.g.</s><s>Pro-C3 and enhanced liver fibrosis biomarker) and imaging studies (ultrasound elastography and magnetic resonance elastography) have already achieved moderate to high accuracies for advanced liver fibrosis and have set a high bar for new diagnostic algorithms by AI.</s><s>That said, there is certainly room for improvement; the existing noninvasive tests tend to have high negative predictive values in excluding advanced fibrosis but rather modest positive predictive values in confirming the diagnosis.</s><s>Moreover, while the existing noninvasive tests have a reasonable performance in cross-sectional studies, few have demonstrated sufficient accuracy as a monitoring tool during longitudinal follow-up.</s></p><p><s>At present, histological improvements in terms of resolution of NASH without worsening of fibrosis or improvement in fibrosis without worsening of NASH remain key endpoints in phase 3 clinical trials for a drug to receive conditional approval from the US Food and Drug Administration subpart H pathway and the European Medicines Agency. <ref type="bibr" target="#b6">7</ref></s><s>Nonetheless, previous studies have demonstrated significant intraobserver and interobserver variability in histological scoring, particularly when suboptimal biopsy specimens are included.</s><s>Compounded with the variabilities in two serial biopsies, the risk of misclassifying treatment response (or no response) is considerable. <ref type="bibr" target="#b9">10</ref></s><s>In addition, a central pathologist may need to review hundreds to thousands of slides within a tight time window.</s><s>In this situation, augmentation by AI to produce quick and reproducible scores is particularly attractive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Principles of artificial intelligence</head><p><s>Basic principles.</s><s>Artificial intelligence including machine learning algorithms and deep neural networks has been increasingly applied for the detection and prediction of NAFLD and fibrosis outcomes in recent years.</s><s>With (large-scale) training cohorts for model development by using AI, the prediction on validation cohorts is probably more accurate compared with traditional biostatistical methods. <ref type="bibr" target="#b10">11</ref></s><s>AI is a data-driven and Artificial intelligence in electronic health record analysis.</s><s>Electronic health records (EHRs) contain patient information of sex, ethnicity, body mass index, genetics, laboratory parameters (e.g.</s><s>viruses and chemicals), comorbidity (such as diabetes), and so forth.</s><s>For this type of data at a single time stamp, the number of variables is usually small (compared with image data), so traditional machine learning methods as shown in Figure <ref type="figure" target="#fig_0">1a</ref> have been widely employed to detect or predict liver diseases including NAFLD and fibrosis. <ref type="bibr" target="#b10">11</ref></s><s>For example, logistic regression, decision tree, random forest, and XGBoost (a gradient-boosted tree model) are evaluated for the task of NASH and NAFLD detection. <ref type="bibr" target="#b11">12</ref></s><s>Logistic regression with logistic loss function is one of the binary classifiers widely used in various medical applications.</s><s>For development of easily interpretable classification model, decision tree trains a tree-like classifier in which each node depends on a variable to make a decision and assign the input with a class label or the following node.</s><s>To increase the generalization accuracy on validation cohorts over decision tree, random forest ensembles multiple decision trees trained on randomly selected features and randomly sampled subset of the training cohort.</s><s>To further increase the detection/prediction performance, XGBoost aggregates each decision tree by correcting the residual error of the preceding ensemble.</s><s>According to the results in Fialoke et al., <ref type="bibr" target="#b11">12</ref> XGBoost achieves the highest accuracy compared with other methods.</s><s>Many variables in EHRs (e.g.</s><s>body mass index, viruses, and chemicals) vary with time.</s><s>Although mean values of EHRs over time could be computed to train traditional machine learning models for detection/prediction, such an approach has not taken full advantages of temporal characteristics for probable better performance.</s><s>Results in a recent study <ref type="bibr" target="#b12">13</ref> show that recurrent neural networks (RNNs) for sequential data processing achieve higher accuracy for detecting NASH from NAFLD patients than traditional machine learning models including logistic regression, random forest, and XGBoost.</s><s>RNNs model temporal dependence over time by using not only the current observation but also the previous state for the current state updating as shown in Figure <ref type="figure" target="#fig_0">1b</ref>.</s><s>As one of the most representative RNN methods, long short-term memory consists of input, output, and forget gates to control the extent on how much short-term and long-term information should be memorized and forgotten, respectively.</s><s>As a result, the RNN approach (e.g.</s><s>long short-term memory) is usually a better choice for the analysis of time series EHR data.</s><s>The advantages and disadvantages of these AI approaches are shown in Table <ref type="table" target="#tab_1">2</ref>.</s></p><p><s>Artificial intelligence in image interpretation.</s><s>For medical image data, for example, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography, and histology, deep neural networks have become a promising approach to greatly improve the classification, detection, and segmentation accuracy. <ref type="bibr" target="#b13">14</ref></s><s>Different from traditional machine learning methods constructing classifiers on human-designed features, convolutional neural networks (CNNs) as the most popular technique of deep neural networks for image processing perform end-to-end learning to automatically extract features by learning multiple convolutional filters and train classifiers at the same time.</s><s>CNNs are composed of convolutional layers (with sparse connectivity and parameter sharing), pooling layers, and fully connected layers.</s><s>Besides the last few fully connected layers, CNNs stack multiple convolutional blocks consisting of convolutional layers and pooling layers alternatively for feature learning from low to high levels.</s><s>The idea of CNNs is illustrated in Figure <ref type="figure" target="#fig_0">1c</ref>.</s><s>By using CT images, CNNs have been employed</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Logistic regression</head><p><s>• Easy to implement, interpret, and very efficient to train.</s></p><p><s>• No assumptions about distributions of classes in feature space.</s></p><p><s>• Easily extend to multiple classes (multinomial regression) and a natural probabilistic view of class predictions.</s></p><p><s>• Provides both the appropriateness of a predictor (coefficient size) and its direction of association (positive or negative).</s></p><p><s>• Very fast at classifying unknown records.</s></p><p><s>• Good accuracy for many simple datasets, and it performs well when the dataset is linearly separable.</s></p><p><s>• Less inclined to overfitting, but it can overfit in high-dimensional datasets.</s></p><p><s>• If the number of observations is lesser than the number of features, logistic regression should not be used; otherwise, it may lead to overfitting.</s></p><p><s>• Constructs linear boundaries.</s></p><p><s>• Assumption of linearity between the dependent variable and the independent variables.</s></p><p><s>• Can only be used to predict discrete functions.</s><s>Hence, the dependent variable of logistic regression is bound to the discrete number set.</s></p><p><s>• Nonlinear problems cannot be solved with logistic regression because it has a linear decision surface.</s></p><p><s>• Requires average or no multicollinearity between independent variables.</s></p><p><s>• Hard to obtain complex relationships using logistic regression.</s><s>More powerful and compact algorithms such as neural networks can easily outperform this algorithm.</s><s>Decision tree</s></p><p><s>• Requires less effort for data preparation during preprocessing.</s></p><p><s>• Does not require normalization of data.</s></p><p><s>• Does not require scaling of data as well.</s></p><p><s>• Missing values in the data also do not affect the process of building a decision tree to any considerable extent.</s></p><p><s>• Intuitive and easy to explain to technical teams as well as stakeholders.</s></p><p><s>• A small change in the data can cause a large change in the structure of the decision tree causing instability.</s></p><p><s>• Calculation can go far more complex compared with other algorithms.</s></p><p><s>• Often involves higher time to train the model.</s></p><p><s>• Training is relatively expensive as the complexity and time have taken are more.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Random forest</head><p><s>• Reduces overfitting problem in decision trees and also reduces the variance and therefore improves the accuracy.</s></p><p><s>• Can be used to solve both classification and regression problems.</s></p><p><s>• Works well with both categorical and continuous variables.</s></p><p><s>• Automatically handles missing values.</s></p><p><s>• No feature scaling (standardization and normalization).</s></p><p><s>• Handles nonlinear parameters efficiently.</s></p><p><s>• Robust to outliers and can handle them automatically.</s></p><p><s>• Very stable.</s><s>Even if a new data point is introduced in the dataset, the overall algorithm is not affected much because the new data may impact one tree, but it is very hard for it to impact all the trees.</s></p><p><s>• Less impacted by noise.</s></p><p><s>• Complexity: It creates many trees (unlike only one tree in case of decision tree) and combines their outputs.</s><s>By default, it creates 100 trees in Python sklearn library.</s><s>To do so, this algorithm requires much more computational power and resources.</s><s>On the other hand, decision tree is simple and does not require so much computational resources.</s></p><p><s>• Longer training period: It requires much more time to train as compared with decision trees as it generates many trees (instead of one tree in case of decision tree) and makes decision on the majority of votes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>XGBoost</head><p><s>• Easy to read and interpret algorithm.</s></p><p><s>• Efficient prediction capability through the use of its clone methods.</s></p><p><s>• A resilient method that curbs overfitting easily.</s></p><p><s>• Sensitive to outliers because every classifier is obliged to fix the errors in the predecessors.</s></p><p><s>• Almost impossible to scale up, as every estimator bases its correctness on the previous predictors, thus making the procedure difficult to streamline.</s><s>Recurrent neural networks (RNNs)</s></p><p><s>• Can process inputs of any length.</s></p><p><s>• Modeled to remember each information throughout the time, which is very helpful in any time series predictor.</s></p><p><s>• Model size does not increase with input size.</s></p><p><s>• Weights can be shared across the time steps.</s></p><p><s>• Can use their internal memory for processing the arbitrary series of inputs, which is not the case with feedforward neural networks.</s></p><p><s>• Because of its recurrent nature, the computation is slow.</s></p><p><s>• Training of RNN models can be difficult.</s></p><p><s>• Difficult to process sequences that are very long.</s></p><p><s>• Prone to problems such as exploding and gradient vanishing.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Convolutional neural networks (CNNs)</head><p><s>• Better performance for image-related vision tasks.</s></p><p><s>• Automatic feature learning compared with the traditional manually designed feature engineering approach.</s></p><p><s>• Reduced size of parameters by weight sharing compared with fully connected neural networks.</s></p><p><s>• Requires a large-scale dataset for training.</s></p><p><s>• The computational complexity is higher than traditional machine learning methods.</s></p><p><s>• There are more hyper-parameters to determine.</s></p><p><s>for fibrosis staging by segmenting the liver region and predicting the stage label. <ref type="bibr" target="#b14">15</ref></s><s>With histology images, histological features of ballooning, inflammation, steatosis, and fibrosis are automatically scored by using CNNs. <ref type="bibr" target="#b15">16</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Artificial intelligence and non-alcoholic fatty liver disease</head><p><s>Most of the prediction models for NAFLD were derived and validated against liver biopsy or radiological tests using conventional statistical logistic regression analysis to identify factors associated with NAFLD and c-statistics to evaluate the overall accuracy (Table <ref type="table" target="#tab_1">2</ref>). <ref type="bibr" target="#b16">17</ref></s><s>Optimal cutoff values are often defined according to those with high sensitivity, specificity, a maximum sum of sensitivity and specificity, and a maximum diagnostic accuracy (the sum of true positives and true negatives over the total number of patients), according to the diagnostic target.</s></p><p><s>Artificial intelligence may be applied in either histological or clinical scoring systems.</s><s>AI assessment of histological features of NAFLD may reduce human variability and provide continuous rather than semiquantitative measurement of these features, with accuracy ranging from 82% to 89%. <ref type="bibr" target="#b17">18</ref></s><s>AI software may identify histological features of NAFLD with high levels of interobserver and intraobserver agreement (0.95 to 0.99). <ref type="bibr" target="#b18">19</ref></s><s>lectronic health records can provide robust and comprehensive demographic and laboratory data in thousands and millions of patients, yet clinical observations and anthropometric measurements are often missing.</s><s>A clinical decision support system has an accuracy of 91.7% to diagnose NAFLD. <ref type="bibr" target="#b19">20</ref></s><s>NAFLD ridge score was developed with machine learning approach based only on five laboratory parameters and one comorbidity-alanine aminotransferase, high-density lipoprotein cholesterol, triglyceride, hemoglobin A1c, white blood cell count, and the presence of hypertension -using proton magnetic resonance spectroscopy ( 1 H-MRS) as the reference standard. <ref type="bibr" target="#b20">21</ref></s><s>The score has an excellent negative predictive value of 96% to exclude NAFLD.</s></p><p><s>The histology-based AI models provide automated and objective diagnosis of NAFLD in selected patients who have undergone liver biopsy, whereas EMR-based AI models suit the need of large-scale epidemiological screening and risk stratification.</s><s>We should be cautious in applying these AI models, as the reference standard may not be 100% correct (as in the case of histological features).</s><s>Also, the general population of whom these AI models to be applied may have very different risk profile and clinical characteristics, in particular alcohol consumption and metabolic profile, when compared with the derivation cohorts.</s><s>These models are mostly derived from cross-sectional cohorts at a particular time point, while in real life, all the factors included in the models are highly dynamic.</s></p><p><s>Non-alcoholic fatty liver disease used to be a diagnosis of exclusion.</s><s>Recently, a group of expert hepatologists proposed to rename the condition as metabolic dysfunction-associated fatty liver disease (MAFLD) and require the inclusion of metabolic risk factors in its diagnosis. <ref type="bibr" target="#b21">22</ref></s><s>]<ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref> In a population study from our group, we found that the prevalence of MAFLD and NAFLD was similar despite the slightly different definitions, whereas the new MAFLD definition may reduce the incidence of new-onset disease from 13.8% to 10.4% in 3-5years. <ref type="bibr" target="#b26">27</ref></s><s>Importantly, people who have fatty liver but no or mild metabolic risk factors are unlikely to have severe liver disease.</s><s>It is thus reasonable not to classify them as having a disease.</s><s>How this new definition of MAFLD affecting the performance of AI models remains unclear.</s><s>Future studies may compare the diagnostic performance of AI models according to the definitions and diagnostic criteria of NAFLD and MAFLD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Artificial intelligence and fibrosis</head><p><s>Assessing the severity of NAFLD is not only prognostically important but also a mandatory step to select patients for novel pharmacological treatments for NASH in clinical practice and research studies (Table <ref type="table" target="#tab_2">3</ref>). <ref type="bibr" target="#b8">9</ref></s><s>AI models for liver fibrosis may be built on histology, clinical and laboratory parameters, and imaging.</s><s>A handful of laboratory parameters, ranging from common parameters (such as aminotransferases) to specialized fibrosis biomarkers (e.g.</s><s>hyaluronic acid and Pro-C3), are found to have modest to moderate accuracy to detect advanced fibrosis. <ref type="bibr" target="#b27">28</ref></s><s>n integrated AI-based automated tool is able to detect and quantify liver fibrosis through collagen proportionate area and assess its architectural pattern in liver biopsy with accuracy above 90% for bridging fibrosis and histological cirrhosis. <ref type="bibr" target="#b28">29</ref></s><s>A refined AI-based algorithm (qFibrosis) incorporated 26 novel histological periportal parameters that showed a good discriminatory ability for earlier stages of liver fibrosis in NAFLD (F1 vs F2). <ref type="bibr" target="#b29">30</ref> This would be particularly useful for screening patients for NAFLD clinical trials, which specifically target patients with F2 fibrosis.</s></p><p><s>There are a number of platforms to evaluate liver fibrosis and other histological features in patients with NAFLD.</s><s>The dual-photon microscopy system looks at unstained slides and identifies various features of fibrosis including the length, thickness, and morphology of different fibrils (Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>In a study of 344 patients with biopsy-proven NAFLD, the system had 88-96% sensitivity and 78-91% specificity for diagnosing different fibrosis stages, using histological scoring as the reference standard. <ref type="bibr" target="#b30">31</ref></s><s>Importantly, these AI-detected fibrosis patterns predicted cirrhotic complications and hepatocellular carcinoma during follow-up.</s><s>Recently, the system has been expanded to quantify other histological features including steatosis, lobular inflammation, and ballooning (coined qFIBS), although the discrimination for severe inflammation and ballooning requires further refinement. <ref type="bibr" target="#b31">32</ref></s><s>ther investigators and companies have relied instead on digitized images of stained biopsy slides. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b32">33</ref></s><s>While most systems provide a consensus score based on the most likely fibrosis stage, the PathAI system describes the proportion of areas with features most resembling different particular fibrosis stages.</s><s>In a combined analysis of a phase 2b and a phase 3 NASH trial, the change in AI-based features between baseline and follow-up liver biopsies correlated better with changes in the other noninvasive tests than traditional histological scoring, suggesting that AI may be more sensitive and specific as a method to evaluate treatment response. <ref type="bibr" target="#b32">33</ref></s><s>ne notable difficulty in developing AI-based histology assessment is the lack of a real gold standard.</s><s>Consensus scoring by more than one pathologist can reduce but not eliminate interobserver variability.</s><s>In the dual-photon microscopy example, investigators adopted the "fair umpire" method using transient elastography as an additional reference. <ref type="bibr" target="#b30">31</ref></s><s>Using this concept, the reference test does not have to be perfect; it only needs to have readiscriminating power for the outcome of interest and is not mechanistically related to the tests under evaluation.</s><s>In this situation, the reference test should have the strongest correlation with the best diagnostic test.</s><s>Nevertheless, these AI-based algorithms would eventually need to demonstrate an association with clinical outcomes, as is currently required for other surrogate endpoints in clinical trials.</s></p><p><s>Combination of imaging modalities and AI improves the accuracy in staging liver fibrosis.</s><s>The performance of combining machine learning with CT and MRI has been evaluated. <ref type="bibr" target="#b19">20</ref></s><s>Their predictions are found to correlate with histological-evaluated liver fibrosis stages.</s><s>Machine learning-based radiomics also play a role in image analysis.</s><s>Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis. <ref type="bibr" target="#b33">34</ref></s><s>Besides that, imaging-based texture analysis-derived parameter, which is a tool of radiomics, combined with machine learning of non-contrast-enhanced T1-weighted magnetic resonance images could be as accurate (82%) as magnetic resonance elastography for liver fibrosis quantification. <ref type="bibr" target="#b34">35</ref></s><s>hese approaches may act as alterative for staging liver fibrosis in different resource settings.</s></p><p><s>The histology-based or imaging-based AI models provide automated and objective detection of significant (F2) to advanced fibrosis (F3-F4) of NAFLD in selected patients who have undergone liver biopsy or MRI.</s><s>Laboratory-based AI models have higher applicability as some common laboratory parameters are part of the routine liver panel.</s><s>Here, applicability has to be balanced with accuracy.</s><s>As histological fibrosis staging remains the gold standard, it is subjected to sampling error.</s><s>Such validated studies are often skewed towards patients with more advanced disease so that the accuracies may differ in the general population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Artificial intelligence and non-alcoholic fatty liver disease-related hepatocellular carcinoma</head><p><s>There has been an increasing trend of NAFLD-related HCC. <ref type="bibr" target="#b7">8</ref> Novel data mining approaches were used to develop prognostic algorithm for these patients. <ref type="bibr" target="#b35">36</ref></s><s>Random forest analysis identified treatment for HCC and serum albumin level as the first and second prognostic factors.</s><s>A decision tree algorithm revealed that patients who underwent curative treatments, namely, surgical resection and radiofrequency ablation, together with a higher serum albumin level had the best prognosis.</s><s>The beauty of these data mining approaches is common clinical parameters and well-defined decision process are involved, so that it can be easily applied in clinical settings.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions and the future</head><p><s>Among the technologies discussed earlier, AI-based image analysis is the closest to clinical application and may transform clinical trials in NASH.</s><s>Apart from using AI to suggest histological scores like what pathologists are currently doing, quantification of the AI features may provide more granular data to determine treatment effects.</s><s>If the latter is to be used as surrogate endpoints, studies should demonstrate an association between these features and clinical outcomes.</s><s>Nevertheless, such an approach still requires liver biopsies.</s><s>The future should be noninvasive tests and algorithms, which may also be AI-based.</s><s>At present, the use of AI to predict NAFLD, fibrosis, and clinical outcomes is still in its infancy.</s><s>Most studies only used cross-sectional data.</s><s>In real life, clinicians do not see patients once but repeatedly.</s><s>AI is in fact well positioned to handle this type of dynamic data, and this should be explored further.</s><s>With concerted effort, these new developments in AI would hopefully improve clinical care and patient experience and outcomes.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Review of artificial intelligence (AI) methods for non-alcoholic fatty liver disease and fibrosis prediction.</s><s>(a) AI methods in electronic health record of single time stamp and (b) time series ( , Cr; , Hb; , Hct; , PLT; , PT; , urea; , WCC).</s><s>(c) AI methods in medical images.</s><s>CT, computed tomography; MR, magnetic resonance.</s><s>[Color figure can be viewed at wileyonlinelibrary.com]</s></p></div></figDesc><graphic coords="3,93.60,486.99,412.10,179.15" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Examples of artificial intelligencebased image analysis of histological slides.</s><s>The second-harmonic generation (SHG)/ two-photon excitation fluorescence (TPEF) imaging-based tool examines unstained slides and identifies collagen fibrils (shown in green in the left panel and white in the middle panel).</s><s>The system quantifies various features of liver fibrosis (right panel) for the determination of overall fibrosis stages (courtesy of Dr Dean Tai, HistoIndex Pte Ltd).</s><s>, central vein collagen; , portal tract collagen; , perisinusoidal collagen.</s><s>[Color figure can be viewed at wileyonlinelibrary.com]</s></p></div></figDesc><graphic coords="7,219.06,60.95,326.55,115.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>The US Food and Drug Administration Biomarkers, EndpointS and other Tools (BEST) biomarker categories and potential contribution from AI in its application in NAFLD</s></p></div></figDesc><table><row><cell>Categories</cell><cell>Meaning</cell><cell>Potential role of AI</cell></row><row><cell>Susceptibility/risk</cell><cell>Potential for developing a disease or medical condition</cell><cell>-Predicting incident NAFLD and fibrosis progression with</cell></row><row><cell></cell><cell></cell><cell>dynamic clinical and laboratory data</cell></row><row><cell>Diagnostic</cell><cell>Detect or confirm presence of a disease or condition</cell><cell>-Highlighting patients likely to have NAFLD and significant</cell></row><row><cell></cell><cell></cell><cell>liver fibrosis based on clinical and laboratory data</cell></row><row><cell></cell><cell></cell><cell>-Highlighting areas suspicious of hepatocellular carcinoma in</cell></row><row><cell></cell><cell></cell><cell>imaging studies</cell></row><row><cell></cell><cell></cell><cell>-Assisting histological interpretation of NAFLD by offering</cell></row><row><cell></cell><cell></cell><cell>suggested scores or highlighting histological features of</cell></row><row><cell></cell><cell></cell><cell>interest (e.g. hepatocyte ballooning and fibrosis)</cell></row><row><cell></cell><cell></cell><cell>-Serving as a high-throughput and reproducible alternative to</cell></row><row><cell></cell><cell></cell><cell>pathologists' assessment in clinical trials involving thousands</cell></row><row><cell></cell><cell></cell><cell>of images</cell></row><row><cell>Monitoring</cell><cell>Serially for assessing status of a disease or medical</cell><cell>-Highlighting suspicion of disease progression based on</cell></row><row><cell></cell><cell>condition</cell><cell>dynamic clinical and laboratory data</cell></row><row><cell></cell><cell></cell><cell>-Serving as a high-throughput and reproducible alternative to</cell></row><row><cell></cell><cell></cell><cell>pathologists' assessment in clinical trials and routine practice</cell></row><row><cell></cell><cell></cell><cell>to detect changes in key histological features</cell></row><row><cell>Prognostic</cell><cell>Likelihood of a clinical event, disease recurrence or</cell><cell>-Predicting future cirrhosis, hepatocellular carcinoma, and</cell></row><row><cell></cell><cell>progression</cell><cell>liver-related complications based on dynamic clinical and</cell></row><row><cell></cell><cell></cell><cell>laboratory data</cell></row><row><cell>Predictive</cell><cell>Favorable or unfavorable effect from exposure to a</cell><cell>-Identifying potential effective treatments or harmful</cell></row><row><cell></cell><cell>medical product or an environmental agent</cell><cell>exposures in real-world big data studies</cell></row><row><cell>Pharmacodynamic/</cell><cell>Biological response has occurred in an individual who has</cell><cell>-Identifying markers or signatures indicating favorable</cell></row><row><cell>response</cell><cell>been exposed to a medical product or an environmental</cell><cell>treatment response in clinical trials and real-world practice</cell></row><row><cell></cell><cell>agent</cell><cell></cell></row><row><cell>Safety</cell><cell>Likelihood, presence, or extent of toxicity as an adverse</cell><cell>-Identifying markers or signatures predicting adverse events</cell></row><row><cell></cell><cell>effect</cell><cell>to a therapeutic agent in clinical trials and real-world practice</cell></row><row><cell cols="2">AI, artificial intelligence; NAFLD, non-alcoholic fatty liver disease.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Advantages and disadvantages of various AI approaches</s></p></div></figDesc><table><row><cell>AI approach</cell><cell>Advantages</cell><cell>Disadvantages</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Studies on the use of to evaluate NAFLD MRS, proton magnetic resonance spectroscopy; AI, artificial intelligence; GLCM, gray-level co-occurrence matrix; MR, magnetic resonance; MRI, magnetic resonance imaging; NAFLD, non-alcoholic fatty liver disease.</s></p></div></figDesc><table><row><cell>Gold standard N Accuracy</cell><cell></cell><cell>Liver biopsy 162 92%</cell><cell>1 H-MRS 922 87-88%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Liver biopsy 126 79%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Liver biopsy 62 (16/25.8% NAFLD) 82%</cell><cell></cell><cell></cell><cell></cell><cell>Liver biopsy 47 82-89%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Liver biopsy 246 92-97%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Liver biopsy 987 annotations Periportal fibrosis 78.6%</cell><cell>Pericellular fibrosis 83.3%</cell><cell>Portal fibrosis 86.4%</cell><cell>Bridging fibrosis/cirrhosis &gt; 90%</cell><cell></cell><cell>Liver biopsy 160 95-99% (F1 vs F2)</cell><cell></cell><cell></cell><cell>Liver biopsy 344 patients 87.6-96.5% (F0-F1 vs F2-F4)</cell><cell>(428 liver biopsies) 89.7-96.5% (F0-F2 vs F3-F4)</cell><cell>88.3-96.6% (F0-F3 vs F4)</cell><cell>Liver biopsy 605 patients Not reported in the abstract</cell><cell></cell><cell></cell></row><row><cell>Author (year) Country/region Type of parameters Parameters in the model</cell><cell>Prediction of NAFLD by clinical features</cell><cell>Douali et al. (2013) France Laboratory/clinical (Details not reported)</cell><cell>Yip et al. (2017) Hong Kong Laboratory/clinical • Alanine aminotransferase</cell><cell>• High-density lipoprotein cholesterol</cell><cell>• Triglyceride</cell><cell>• Hemoglobin A1c</cell><cell>• White blood cell count</cell><cell>• Presence of hypertension</cell><cell>Prediction of liver fibrosis by clinical features</cell><cell>Sowa et al. (2013) Germany Laboratory/clinical • Alanine aminotransferase</cell><cell>• Aspartate aminotransferase</cell><cell>• Hyaluronic acid</cell><cell>• Apoptosis marker M30</cell><cell>• Apoptosis marker M65</cell><cell>Schawkat et al. (2020) Switzerland/USA MRI • T1-weighted fat-saturated images</cell><cell>• T2-weighted fat-saturated images with MR</cell><cell>elastography</cell><cell>AI-based histology assessment</cell><cell>Vanderbeck et al. (2013) USA Histology • Morphological features</cell><cell>• Texture</cell><cell>• GLCM and its statistics</cell><cell>• N-jet</cell><cell>• Nuclei density</cell><cell>Forlano et al. (2019) UK Histology Automated quantification (in %)</cell><cell>• Fat</cell><cell>• Inflammation</cell><cell>• Ballooning</cell><cell>• Collagen proportional area (CPA) for fibrosis</cell><cell>Gawrieh et al. (2020) USA Histology Fibrosis quantification</cell><cell>• CPA</cell><cell>Fibrosis pattern</cell><cell>• Morphological structures</cell><cell>• Textural properties</cell><cell>Leow et al. (2020) China/Singapore Histology qFibrosis algorithm by dual-photon microscopy</cell><cell>• 28 newly created periportal parameters</cell><cell>• 28 altered perisinusoidal parameters</cell><cell>Wang et al. (2020) China Histology • 25 fibrosis-related parameters (q-FPs)</cell><cell>by dual-photon microscopy</cell><cell></cell><cell>Taylor-Weiner et al. (2020) America/Asia/Europe Histology PathAI</cell><cell>• Digitized images of liver biopsy</cell><cell>• Assigns a fibrosis stage to each small areas</cell><cell>• Percentage tissue area of predicted fibrosis stage</cell></row></table><note><p><s>1 H-</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">Journal of Gastroenterology and Hepatology 36 (2021) 543-550 © 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd 14401746, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/jgh.15385 by Universidad Politecnica De Madrid, Wiley Online Library on [07/02/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
		</body>
		<back>

			<div type="funding">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>This study was funded in part by the Health and Medical Research Fund (HMRF) of Food and Health Bureau, Hong Kong (project reference number: 07180216) to Grace Lai-Hung Wong.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis</title>
		<author>
			<persName><forename type="first">Zobair</forename><surname>Younossi</surname></persName>
			<idno type="ORCID">0000-0001-9313-577X</idno>
		</author>
		<author>
			<persName><forename type="first">Frank</forename><surname>Tacke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marco</forename><surname>Arrese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Barjesh</forename><surname>Chander Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ibrahim</forename><surname>Mostafa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elisabetta</forename><surname>Bugianesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vincent</forename><surname>Wai-Sun Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yusuf</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jiangao</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Miriam</forename><forename type="middle">B</forename><surname>Vos</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.30251</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<title level="j" type="abbrev">Hepatology</title>
		<idno type="ISSN">0270-9139</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2672" to="2682" />
			<date type="published" when="2019-05-29">2019</date>
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Younossi Z, Tacke F, Arrese M et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2019; 69: 2672-82.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">Jie</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Biyao</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yee</forename><forename type="middle">Hui</forename><surname>Yeo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuemin</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaoyu</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dong</forename><forename type="middle">Hyun</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hideki</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuankai</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Leslie</forename><forename type="middle">Y</forename><surname>Kam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fanpu</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaohe</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nicholas</forename><surname>Chien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mike</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eiichi</forename><surname>Ogawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Changqing</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xia</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christopher</forename><forename type="middle">D</forename><surname>Stave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Linda</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Scott</forename><surname>Barnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hirokazu</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Norihiro</forename><surname>Furusyo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuichiro</forename><surname>Eguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yao-Chun</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Teng-Yu</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wanhua</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chengyong</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dae</forename><forename type="middle">Won</forename><surname>Jun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hidenori</forename><surname>Toyoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ramsey</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Qiang</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mindie</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-1253(19)30039-1</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Gastroenterology &amp; Hepatology</title>
		<title level="j" type="abbrev">The Lancet Gastroenterology &amp; Hepatology</title>
		<idno type="ISSN">2468-1253</idno>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="389" to="398" />
			<date type="published" when="2019-05">2019</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Li J, Zou B, Yeo YH et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2019; 4: 389-98.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States</title>
		<author>
			<persName><forename type="first">Zobair</forename><forename type="middle">M</forename><surname>Younossi</surname></persName>
			<idno type="ORCID">0000-0001-9313-577X</idno>
		</author>
		<author>
			<persName><forename type="first">Maria</forename><surname>Stepanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Janus</forename><surname>Ong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Greg</forename><surname>Trimble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Saleh</forename><surname>Alqahtani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Issah</forename><surname>Younossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aijaz</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Andrei</forename><surname>Racila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Linda</forename><surname>Henry</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2020.05.064</idno>
		<ptr target="https://doi.org/10.1016/j.cgh.2020.05.064.Onlineaheadofprint" />
	</analytic>
	<monogr>
		<title level="j">Clinical Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">Clinical Gastroenterology and Hepatology</title>
		<idno type="ISSN">1542-3565</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="580" to="589.e5" />
			<date type="published" when="2020">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Younossi ZM, Stepanova M, Ong J et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin. Gastroenterol. Hepatol. 2020. https://doi.org/ 10.1016/j.cgh.2020.05.064. Online ahead of print.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Nonalcoholic fatty liver disease</title>
		<author>
			<persName><forename type="first">Elizabeth</forename><forename type="middle">M</forename><surname>Brunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Null-</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Valerio</forename><surname>Nobili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Silvia</forename><surname>Sookoian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacquelyn</forename><forename type="middle">J</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elisabetta</forename><surname>Bugianesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Claude</forename><forename type="middle">B</forename><surname>Sirlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brent</forename><forename type="middle">A</forename><surname>Neuschwander-Tetri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mary</forename><forename type="middle">E</forename><surname>Rinella</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrdp.2015.80</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Disease Primers</title>
		<title level="j" type="abbrev">Nat Rev Dis Primers</title>
		<idno type="ISSNe">2056-676X</idno>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">15080</biblScope>
			<date type="published" when="2015-12-17">2015</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Brunt EM, Wong VW, Nobili V et al. Nonalcoholic fatty liver disease. Nat. Rev. Dis. Primers 2015; 1: 15080.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis</title>
		<author>
			<persName><forename type="first">Rod</forename><forename type="middle">S</forename><surname>Taylor</surname></persName>
			<idno type="ORCID">0000-0002-3043-6011</idno>
		</author>
		<author>
			<persName><forename type="first">Rebecca</forename><forename type="middle">J</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sue</forename><surname>Bayliss</surname></persName>
			<idno type="ORCID">0000-0003-3025-9323</idno>
		</author>
		<author>
			<persName><forename type="first">Hannes</forename><surname>Hagström</surname></persName>
			<idno type="ORCID">0000-0002-8474-1759</idno>
		</author>
		<author>
			<persName><forename type="first">Patrik</forename><surname>Nasr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jorn</forename><forename type="middle">M</forename><surname>Schattenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Masatoshi</forename><surname>Ishigami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hidenori</forename><surname>Toyoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vincent</forename><surname>Wai-Sun Wong</surname></persName>
			<idno type="ORCID">0000-0003-2215-9410</idno>
		</author>
		<author>
			<persName><forename type="first">Noam</forename><surname>Peleg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Amir</forename><surname>Shlomai</surname></persName>
			<idno type="ORCID">0000-0001-7437-9381</idno>
		</author>
		<author>
			<persName><forename type="first">Giada</forename><surname>Sebastiani</surname></persName>
			<idno type="ORCID">0000-0003-2655-8283</idno>
		</author>
		<author>
			<persName><forename type="first">Yuya</forename><surname>Seko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Neeraj</forename><surname>Bhala</surname></persName>
			<idno type="ORCID">0000-0003-2502-1177</idno>
		</author>
		<author>
			<persName><forename type="first">Zobair</forename><forename type="middle">M</forename><surname>Younossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Quentin</forename><forename type="middle">M</forename><surname>Anstee</surname></persName>
			<idno type="ORCID">0000-0002-9518-0088</idno>
		</author>
		<author>
			<persName><forename type="first">Stuart</forename><surname>Mcpherson</surname></persName>
			<idno type="ORCID">0000-0002-5638-2453</idno>
		</author>
		<author>
			<persName><forename type="first">Philip</forename><forename type="middle">N</forename><surname>Newsome</surname></persName>
			<idno type="ORCID">0000-0001-6085-3652</idno>
		</author>
		<idno type="DOI">10.1053/j.gastro.2020.01.043</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<title level="j" type="abbrev">Gastroenterology</title>
		<idno type="ISSN">0016-5085</idno>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1611" to="1625.e12" />
			<date type="published" when="2020-05">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Taylor RS, Taylor RJ, Bayliss S et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158: 1611-25, e12.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study</title>
		<author>
			<persName><forename type="first">Eduardo</forename><surname>Vilar-Gomez</surname></persName>
			<idno type="ORCID">0000-0003-1435-4013</idno>
		</author>
		<author>
			<persName><forename type="first">Luis</forename><surname>Calzadilla-Bertot</surname></persName>
			<idno type="ORCID">0000-0001-9221-0272</idno>
		</author>
		<author>
			<persName><forename type="first">Vincent</forename><surname>Wai-Sun Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marlen</forename><surname>Castellanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rocio</forename><surname>Aller-De La Fuente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mayada</forename><surname>Metwally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mohammed</forename><surname>Eslam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Licet</forename><surname>Gonzalez-Fabian</surname></persName>
			<idno type="ORCID">0000-0003-1143-2135</idno>
		</author>
		<author>
			<persName><forename type="first">María</forename><surname>Alvarez-Quiñones Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Antonio</forename><forename type="middle">Felix</forename><surname>Conde-Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bastiaan</forename><surname>De Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Duncan</forename><surname>Mcleod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anthony</forename><forename type="middle">Wing</forename><surname>Hung Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Naga</forename><surname>Chalasani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Leon</forename><forename type="middle">A</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Manuel</forename><surname>Romero-Gomez</surname></persName>
			<idno type="ORCID">0000-0001-8494-8947</idno>
		</author>
		<idno type="DOI">10.1053/j.gastro.2018.04.034</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<title level="j" type="abbrev">Gastroenterology</title>
		<idno type="ISSN">0016-5085</idno>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="443" to="457.e17" />
			<date type="published" when="2018-08">2018</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Vilar-Gomez E, Calzadilla-Bertot L, Wong VW et Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 2018; 155: 443-57, e17.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Pathogenesis and novel treatment options for non-alcoholic steatohepatitis</title>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shiv</forename><surname>Chitturi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jun</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Henry Lik-Yuen</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Geoffrey</forename><forename type="middle">C</forename><surname>Farrell</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-1253(16)30011-5</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Gastroenterology &amp; Hepatology</title>
		<title level="j" type="abbrev">The Lancet Gastroenterology &amp; Hepatology</title>
		<idno type="ISSN">2468-1253</idno>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="56" to="67" />
			<date type="published" when="2016-09">2016</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong VW, Chitturi S, Wong GL et al. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol. Hepatol. 2016; 1: 56-67.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment</title>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0003-2215-9410</idno>
		</author>
		<author>
			<persName><forename type="first">Wah-Kheong</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shiv</forename><surname>Chitturi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yogesh</forename><surname>Chawla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yock</forename><forename type="middle">Young</forename><surname>Dan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajay</forename><surname>Duseja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jiangao</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Khean-Lee</forename><surname>Goh</surname></persName>
			<idno type="ORCID">0000-0002-9965-1561</idno>
		</author>
		<author>
			<persName><forename type="first">Masahide</forename><surname>Hamaguchi</surname></persName>
			<idno type="ORCID">0000-0002-8651-4445</idno>
		</author>
		<author>
			<persName><forename type="first">Etsuko</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Seung</forename><forename type="middle">Up</forename><surname>Kim</surname></persName>
			<idno type="ORCID">0000-0002-9658-8050</idno>
		</author>
		<author>
			<persName><forename type="first">Laurentius</forename><forename type="middle">Adrianto</forename><surname>Lesmana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yu-Cheng</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chun-Jen</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yen-Hsuan</forename><surname>Ni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jose</forename><surname>Sollano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Simon Kin-Hung</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Henry Lik-Yuen</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Geoff</forename><surname>Farrell</surname></persName>
		</author>
		<idno type="DOI">10.1111/jgh.13857</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">Journal of Gastroenterology and Hepatology</title>
		<idno type="ISSN">0815-9319</idno>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="70" to="85" />
			<date type="published" when="2018">2018</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong VW, Chan WK, Chitturi S et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 1: definition, risk factors and assessment. J. Gastroenterol. Hepatol. 2018; 33: 70-85.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Noninvasive biomarkers in NAFLD and NASH — current progress and future promise</title>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0003-2215-9410</idno>
		</author>
		<author>
			<persName><forename type="first">Leon</forename><forename type="middle">A</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Victor</forename><surname>De Lédinghen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0002-2863-9389</idno>
		</author>
		<author>
			<persName><forename type="first">Silvia</forename><surname>Sookoian</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41575-018-0014-9</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Gastroenterology &amp; Hepatology</title>
		<title level="j" type="abbrev">Nat Rev Gastroenterol Hepatol</title>
		<idno type="ISSN">1759-5045</idno>
		<idno type="ISSNe">1759-5053</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="461" to="478" />
			<date type="published" when="2018-05-29">2018</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong VW, Adams LA, de Ledinghen V et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 2018; 15: 461-78.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials</title>
		<author>
			<persName><forename type="first">Beth</forename><forename type="middle">A</forename><surname>Davison</surname></persName>
			<idno type="ORCID">0000-0003-2374-6449</idno>
		</author>
		<author>
			<persName><forename type="first">Stephen</forename><forename type="middle">A</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gad</forename><surname>Cotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Naim</forename><surname>Alkhouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Arun</forename><surname>Sanyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christopher</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jerry</forename><forename type="middle">R</forename><surname>Colca</surname></persName>
			<idno type="ORCID">0000-0003-3933-8626</idno>
		</author>
		<author>
			<persName><forename type="first">Julie</forename><surname>Iwashita</surname></persName>
			<idno type="ORCID">0000-0002-8399-6944</idno>
		</author>
		<author>
			<persName><forename type="first">Gary</forename><forename type="middle">G</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Howard</forename><forename type="middle">C</forename><surname>Dittrich</surname></persName>
			<idno type="ORCID">0000-0002-6049-8328</idno>
		</author>
		<idno type="DOI">10.1016/j.jhep.2020.06.025</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Hepatology</title>
		<title level="j" type="abbrev">Journal of Hepatology</title>
		<idno type="ISSN">0168-8278</idno>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1322" to="1332" />
			<date type="published" when="2020-12">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Davison BA, Harrison SA, Cotter G et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 2020; 73: 1322-32.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review</title>
		<author>
			<persName><forename type="first">Ashley</forename><surname>Spann</surname></persName>
			<idno type="ORCID">0000-0003-1278-7712</idno>
		</author>
		<author>
			<persName><forename type="first">Angeline</forename><surname>Yasodhara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Justin</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kymberly</forename><surname>Watt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bo</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anna</forename><surname>Goldenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mamatha</forename><surname>Bhat</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.31103</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<title level="j" type="abbrev">Hepatology</title>
		<idno type="ISSN">0270-9139</idno>
		<idno type="ISSNe">1527-3350</idno>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1093" to="1105" />
			<date type="published" when="2020-03">2020</date>
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Spann A, Yasodhara A, Kang J et al. Applying machine learning in liver disease and transplantation: a comprehensive review. Hepatology 2020; 71: 1093-105.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Application of machine learning methods to predict non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver (NAFL) patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fialoke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Malarstig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AMIA Annu. Symp. Proc</title>
		<imprint>
			<biblScope unit="volume">2018</biblScope>
			<biblScope unit="page" from="430" to="439" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fialoke S, Malarstig A, Miller MR et al. Application of machine learning methods to predict non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver (NAFL) patients. AMIA Annu. Symp. Proc. 2018; 2018: 430-9.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A Deep Learning Approach for Classifying Nonalcoholic Steatohepatitis Patients from Nonalcoholic Fatty Liver Disease Patients Using Electronic Medical Records</title>
		<author>
			<persName><forename type="first">Pradyumna</forename><forename type="middle">Byappanahalli</forename><surname>Suresha</surname></persName>
			<idno type="ORCID">0000-0003-1809-6613</idno>
		</author>
		<author>
			<persName><forename type="first">Yunlong</forename><surname>Wang</surname></persName>
			<idno type="ORCID">0000-0003-2186-9306</idno>
		</author>
		<author>
			<persName><forename type="first">Cao</forename><surname>Xiao</surname></persName>
			<idno type="ORCID">0000-0002-3869-6942</idno>
		</author>
		<author>
			<persName><forename type="first">Lucas</forename><surname>Glass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yilian</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gari</forename><forename type="middle">D</forename><surname>Clifford</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-030-53352-6_10</idno>
	</analytic>
	<monogr>
		<title level="m">Explainable AI in Healthcare and Medicine</title>
				<imprint>
			<publisher>Springer International Publishing</publisher>
			<date type="published" when="2020-11-03" />
			<biblScope unit="volume">2020</biblScope>
			<biblScope unit="page" from="107" to="113" />
		</imprint>
	</monogr>
	<note type="raw_reference">Suresha PB, Wang Y, Xiao C et al. A deep learning approach for classifying nonalcoholic steatohepatitis patients from nonalcoholic fatty liver disease patients using electronic medical records. In Explainable AI in Healthc. Med. 2020: 107-13.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Artificial intelligence in medical imaging of the liver</title>
		<author>
			<persName><forename type="first">Li-Qiang</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jia-Yu</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Song-Yuan</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ge-Ge</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Qi</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">You-Bin</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xing-Long</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xin-Wu</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christoph</forename><forename type="middle">F</forename><surname>Dietrich</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v25.i6.672</idno>
	</analytic>
	<monogr>
		<title level="j">World Journal of Gastroenterology</title>
		<title level="j" type="abbrev">WJG</title>
		<idno type="ISSN">1007-9327</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="672" to="682" />
			<date type="published" when="2019-02-14">2019</date>
			<publisher>Baishideng Publishing Group Inc.</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhou LQ, Wang JY, Yu SY et al. Artificial intelligence in medical imaging of the liver. World J. Gastroenterol. 2019; 25: 672-82.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Development and Validation of a Deep Learning System for Staging Liver Fibrosis by Using Contrast Agent–enhanced CT Images in the Liver</title>
		<author>
			<persName><forename type="first">Kyu</forename><forename type="middle">Jin</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jong</forename><forename type="middle">Keon</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Seung</forename><forename type="middle">Soo</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yu</forename><forename type="middle">Sub</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Woo</forename><forename type="middle">Hyun</forename><surname>Shim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ho</forename><forename type="middle">Sung</forename><surname>Kim</surname></persName>
			<idno type="ORCID">0000-0002-9477-7421</idno>
		</author>
		<author>
			<persName><forename type="first">Jessica</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin-Young</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yedaun</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bo-Kyeong</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">Hee</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">So</forename><forename type="middle">Yeon</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eun</forename><forename type="middle">Sil</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1148/radiol.2018180763</idno>
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<title level="j" type="abbrev">Radiology</title>
		<idno type="ISSN">0033-8419</idno>
		<idno type="ISSNe">1527-1315</idno>
		<imprint>
			<biblScope unit="volume">289</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="688" to="697" />
			<date type="published" when="2018-12">2018</date>
			<publisher>Radiological Society of North America (RSNA)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Choi KJ, Jang JK, Lee SS et al. Development and validation of a deep learning system for staging liver fibrosis by using contrast agent-enhanced CT images in the liver. Radiology 2018; 289: 688-97.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Deep learning enables pathologist-like scoring of NASH models</title>
		<author>
			<persName><forename type="first">Fabian</forename><surname>Heinemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gerald</forename><surname>Birk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Birgit</forename><surname>Stierstorfer</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-019-54904-6</idno>
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<title level="j" type="abbrev">Sci Rep</title>
		<idno type="ISSNe">2045-2322</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">18454</biblScope>
			<date type="published" when="2019-12-05">2019</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Heinemann F, Birk G, Stierstorfer B. Deep learning enables pathologist-like scoring of NASH models. Sci. Rep. 2019; 9: 18454.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease</title>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julien</forename><surname>Vergniol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Juliette</forename><surname>Foucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Henry Lik-Yuen</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brigitte</forename><surname>Le Bail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Paul Cheung-Lung</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mathurin</forename><surname>Kowo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anthony Wing-Hung</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wassil</forename><surname>Merrouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joseph Jao-Yiu</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Victor</forename><surname>De Lédinghen</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.23312</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<title level="j" type="abbrev">Hepatology</title>
		<idno type="ISSN">0270-9139</idno>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="454" to="462" />
			<date type="published" when="2010">2010</date>
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Automatic classification of white regions in liver biopsies by supervised machine learning</title>
		<author>
			<persName><forename type="first">Scott</forename><surname>Vanderbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joseph</forename><surname>Bockhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Richard</forename><surname>Komorowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">E</forename><surname>Kleiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Samer</forename><surname>Gawrieh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.humpath.2013.11.011</idno>
	</analytic>
	<monogr>
		<title level="j">Human Pathology</title>
		<title level="j" type="abbrev">Human Pathology</title>
		<idno type="ISSN">0046-8177</idno>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="785" to="792" />
			<date type="published" when="2014-04">2014</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Vanderbeck S, Bockhorst J, Komorowski R et al. Automatic classification of white regions in liver biopsies by supervised machine learning. Hum. Pathol. 2014; 45: 785-92.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease</title>
		<author>
			<persName><forename type="first">Roberta</forename><surname>Forlano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Benjamin</forename><forename type="middle">H</forename><surname>Mullish</surname></persName>
			<idno type="ORCID">0000-0001-6300-3100</idno>
		</author>
		<author>
			<persName><forename type="first">Nikolaos</forename><surname>Giannakeas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">James</forename><forename type="middle">B</forename><surname>Maurice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Napat</forename><surname>Angkathunyakul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Josephine</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alexandros</forename><forename type="middle">T</forename><surname>Tzallas</surname></persName>
			<idno type="ORCID">0000-0001-9043-1290</idno>
		</author>
		<author>
			<persName><forename type="first">Markos</forename><surname>Tsipouras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><surname>Yee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mark</forename><forename type="middle">R</forename><surname>Thursz</surname></persName>
			<idno type="ORCID">0000-0002-8218-192X</idno>
		</author>
		<author>
			<persName><forename type="first">Robert</forename><forename type="middle">D</forename><surname>Goldin</surname></persName>
			<idno type="ORCID">0000-0001-5184-4519</idno>
		</author>
		<author>
			<persName><forename type="first">Pinelopi</forename><surname>Manousou</surname></persName>
			<idno type="ORCID">0000-0002-5363-1565</idno>
		</author>
		<idno type="DOI">10.1016/j.cgh.2019.12.025</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">Clinical Gastroenterology and Hepatology</title>
		<idno type="ISSN">1542-3565</idno>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2081" to="2090.e9" />
			<date type="published" when="2020-08">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Forlano R, Mullish BH, Giannakeas N et al. High-throughput, machine learning-based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2020; 18: 2081-90, e9.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Formalization of Clinical Practice Guidelines: Nonalcoholic Steatohepatitis Diagnosis Model-Related Personalized Medicine</title>
		<author>
			<persName><forename type="first">Nassim</forename><surname>Douali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Meriem</forename><surname>Abdennour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jean</forename><forename type="middle">Daniel</forename><surname>Zucker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marie-Christine</forename><surname>Jaulent</surname></persName>
		</author>
		<idno type="DOI">10.24105/ejbi.2014.10.1.3</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal for Biomedical Informatics</title>
		<title level="j" type="abbrev">ejbi</title>
		<idno type="ISSNe">1801-5603</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">1178</biblScope>
			<date type="published" when="2013">2013</date>
			<publisher>OMICS Publishing Group</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Douali N, Abdennour M, Sasso M et al. Noninvasive diagnosis of nonalcoholic steatohepatitis disease based on clinical decision support system. Stud. Health Technol. Inform. 2013; 192: 1178.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population</title>
		<author>
			<persName><forename type="first">Null-</forename><forename type="middle">F</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Null-</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0003-2215-9410</idno>
		</author>
		<author>
			<persName><forename type="first">Y-K</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Null-</forename><forename type="middle">Y</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P-C</forename><surname>Yuen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Null-</forename><forename type="middle">H</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0002-2863-9389</idno>
		</author>
		<idno type="DOI">10.1111/apt.14172</idno>
	</analytic>
	<monogr>
		<title level="j">Alimentary Pharmacology &amp; Therapeutics</title>
		<title level="j" type="abbrev">Aliment Pharmacol Ther</title>
		<idno type="ISSN">0269-2813</idno>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="447" to="456" />
			<date type="published" when="2017-06-06">2017</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Yip TC, Ma AJ, Wong VW et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment. Pharmacol. Ther. 2017; 46: 447-56.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”</title>
		<author>
			<persName><forename type="first">Mohammed</forename><surname>Eslam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
			<idno type="ORCID">0000-0002-8421-5476</idno>
		</author>
		<idno type="DOI">10.1016/j.jhep.2020.07.045</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Hepatology</title>
		<title level="j" type="abbrev">Journal of Hepatology</title>
		<idno type="ISSN">0168-8278</idno>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">1575</biblScope>
			<date type="published" when="2020-12">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 2020; 73: 202-9.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Comparison of MAFLD and NAFLD diagnostic criteria in real world</title>
		<author>
			<persName><forename type="first">Su</forename><surname>Lin</surname></persName>
			<idno type="ORCID">0000-0001-7517-9859</idno>
		</author>
		<author>
			<persName><forename type="first">Jiaofeng</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mingfang</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rahul</forename><surname>Kumar</surname></persName>
			<idno type="ORCID">0000-0002-5092-4821</idno>
		</author>
		<author>
			<persName><forename type="first">Yuxiu</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shiying</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yinlian</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiaozhong</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yueyong</forename><surname>Zhu</surname></persName>
			<idno type="ORCID">0000-0002-0746-4911</idno>
		</author>
		<idno type="DOI">10.1111/liv.14548</idno>
	</analytic>
	<monogr>
		<title level="j">Liver International</title>
		<title level="j" type="abbrev">Liver Int</title>
		<idno type="ISSN">1478-3223</idno>
		<idno type="ISSNe">1478-3231</idno>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2082" to="2089" />
			<date type="published" when="2020-07-26">2020</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Lin S, Huang J, Wang M et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020; 40: 2082-9.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">MAFLD identifies patients with significant hepatic fibrosis better than NAFLD</title>
		<author>
			<persName><forename type="first">Sakura</forename><surname>Yamamura</surname></persName>
			<idno type="ORCID">0000-0002-4879-0254</idno>
		</author>
		<author>
			<persName><forename type="first">Mohammed</forename><surname>Eslam</surname></persName>
			<idno type="ORCID">0000-0002-4315-4144</idno>
		</author>
		<author>
			<persName><forename type="first">Takumi</forename><surname>Kawaguchi</surname></persName>
			<idno type="ORCID">0000-0002-7064-4325</idno>
		</author>
		<author>
			<persName><forename type="first">Tsubasa</forename><surname>Tsutsumi</surname></persName>
			<idno type="ORCID">0000-0001-6571-9874</idno>
		</author>
		<author>
			<persName><forename type="first">Dan</forename><surname>Nakano</surname></persName>
			<idno type="ORCID">0000-0001-6098-1224</idno>
		</author>
		<author>
			<persName><forename type="first">Shinobu</forename><surname>Yoshinaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hirokazu</forename><surname>Takahashi</surname></persName>
			<idno type="ORCID">0000-0002-2374-2889</idno>
		</author>
		<author>
			<persName><forename type="first">Keizo</forename><surname>Anzai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Takuji</forename><surname>Torimura</surname></persName>
		</author>
		<idno type="DOI">10.1111/liv.14675</idno>
		<ptr target="https://doi.org/10.1111/liv.14675.Onlineaheadofprint" />
	</analytic>
	<monogr>
		<title level="j">Liver International</title>
		<title level="j" type="abbrev">Liver Int</title>
		<idno type="ISSN">1478-3223</idno>
		<idno type="ISSNe">1478-3231</idno>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3018" to="3030" />
			<date type="published" when="2020-11-30">2020</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Yamamura S, Eslam M, Kawaguchi T et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020. https://doi.org/10.1111/liv.14675. Online ahead of print.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis</title>
		<author>
			<persName><forename type="first">Eduardo</forename><surname>Vilar-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Luis</forename><surname>Calzadilla-Bertot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0003-2215-9410</idno>
		</author>
		<author>
			<persName><forename type="first">Marlen</forename><surname>Castellanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rocio</forename><surname>Aller-De La Fuente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mohammed</forename><surname>Eslam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0002-2863-9389</idno>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
			<idno type="ORCID">0000-0002-8421-5476</idno>
		</author>
		<author>
			<persName><forename type="first">Manuel</forename><surname>Romero-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Leon</forename><forename type="middle">A</forename><surname>Adams</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2020.04.083</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">Clinical Gastroenterology and Hepatology</title>
		<idno type="ISSN">1542-3565</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="136" to="145.e6" />
			<date type="published" when="2021-01">2021</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note>e6</note>
	<note type="raw_reference">Vilar-Gomez E, Calzadilla-Bertot L, Wong VW et al. Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis-related, Child-Pugh A cirrhosis. Clin. Gastroenterol. Hepatol. 2021; 19: 136-45.e6.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">MAFLD and risk of CKD</title>
		<author>
			<persName><forename type="first">Dan-Qin</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yan</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ting-Yao</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kenneth</forename><forename type="middle">I</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rafael</forename><forename type="middle">S</forename><surname>Rios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hao-Yang</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Giovanni</forename><surname>Targher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christopher</forename><forename type="middle">D</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei-Jie</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ming-Hua</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.metabol.2020.154433</idno>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<title level="j" type="abbrev">Metabolism</title>
		<idno type="ISSN">0026-0495</idno>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page">154433</biblScope>
			<date type="published" when="2020">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Sun DQ, Jin Y, Wang TY et al. MAFLD and risk of CKD. Metabolism 2020; 115: 154433.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease</title>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jean</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jill</forename><forename type="middle">M</forename><surname>Abrigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Carmen Ka-Man</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sally She-Ting</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julie Ka-Yu</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Angel Mei-Ling</forename><surname>Chim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alice Pik-Shan</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grace Chung-Yan</forename><surname>Lui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Henry Lik-Yuen</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Winnie Chiu-Wing</forename><surname>Chu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2020.10.046</idno>
		<ptr target="https://doi.org/10.1016/j.cgh.2020.10.046.Onlineaheadofprint" />
	</analytic>
	<monogr>
		<title level="j">Clinical Gastroenterology and Hepatology</title>
		<title level="j" type="abbrev">Clinical Gastroenterology and Hepatology</title>
		<idno type="ISSN">1542-3565</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2161" to="2171.e5" />
			<date type="published" when="2020">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong VW, Wong GL, Woo J et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin. Gastroenterol. Hepatol. 2020. https://doi.org/10.1016/j. cgh.2020.10.046. Online ahead of print.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Novel Algorithm for Non-Invasive Assessment of Fibrosis in NAFLD</title>
		<author>
			<persName><forename type="first">Jan-Peter</forename><surname>Sowa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dominik</forename><surname>Heider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lars</forename><forename type="middle">Peter</forename><surname>Bechmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Guido</forename><surname>Gerken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Daniel</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ali</forename><surname>Canbay</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0062439</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">e62439</biblScope>
			<date type="published" when="2013-04-30">2013</date>
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Sowa JP, Heider D, Bechmann LP et al. Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS ONE 2013; 8: e62439.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD</title>
		<author>
			<persName><forename type="first">Samer</forename><surname>Gawrieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Deepak</forename><surname>Sethunath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Oscar</forename><forename type="middle">W</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">E</forename><surname>Kleiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Raj</forename><surname>Vuppalanchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Naga</forename><surname>Chalasani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mihran</forename><surname>Tuceryan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.anndiagpath.2020.151518</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of Diagnostic Pathology</title>
		<title level="j" type="abbrev">Annals of Diagnostic Pathology</title>
		<idno type="ISSN">1092-9134</idno>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page">151518</biblScope>
			<date type="published" when="2020-08">2020</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Gawrieh S, Sethunath D, Cummings OW et al. Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. Ann. Diagn. Pathol. 2020; 47: 151518.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials</title>
		<author>
			<persName><forename type="first">Wei-Qiang</forename><surname>Leow</surname></persName>
			<idno type="ORCID">0000-0001-6003-9837</idno>
		</author>
		<author>
			<persName><forename type="first">Pierre</forename><surname>Bedossa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Feng</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lai</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kiat-Hon</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei-Keat</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yayun</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jason Pik-Eu</forename><surname>Chang</surname></persName>
			<idno type="ORCID">0000-0002-2702-8412</idno>
		</author>
		<author>
			<persName><forename type="first">Chee-Kiat</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aileen</forename><surname>Wee</surname></persName>
			<idno type="ORCID">0000-0003-3107-7599</idno>
		</author>
		<author>
			<persName><forename type="first">George Boon-Bee</forename><surname>Goh</surname></persName>
		</author>
		<idno type="DOI">10.3390/diagnostics10090643</idno>
	</analytic>
	<monogr>
		<title level="j">Diagnostics</title>
		<title level="j" type="abbrev">Diagnostics</title>
		<idno type="ISSNe">2075-4418</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">643</biblScope>
			<date type="published" when="2020-08-28">2020</date>
			<publisher>MDPI AG</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Leow WQ, Bedossa P, Liu F et al. An improved qFibrosis algorithm for precise screening and enrollment into non-alcoholic steatohepatitis (NASH) clinical trials. Diagnostics (Basel) 2020; 10: 643.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy</title>
		<author>
			<persName><forename type="first">Yan</forename><surname>Wang</surname></persName>
			<idno type="ORCID">0000-0001-6851-3054</idno>
		</author>
		<author>
			<persName><forename type="first">Grace Lai-Hung</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0002-2863-9389</idno>
		</author>
		<author>
			<persName><forename type="first">Fang-Ping</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jian</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Anthony Wing-Hung</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jinlian</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sally She-Ting</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xieer</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yee</forename><forename type="middle">Kit</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao-Tang</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jinlin</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Henry Lik-Yuen</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vincent Wai-Sun</forename><surname>Wong</surname></persName>
			<idno type="ORCID">0000-0003-2215-9410</idno>
		</author>
		<idno type="DOI">10.1136/gutjnl-2019-318841</idno>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<title level="j" type="abbrev">Gut</title>
		<idno type="ISSN">0017-5749</idno>
		<idno type="ISSNe">1468-3288</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1116" to="1126" />
			<date type="published" when="2020">2020</date>
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang Y, Wong GL, He FP et al. Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. Gut. 2020; 69: 1116-26.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis</title>
		<author>
			<persName><forename type="first">Feng</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><forename type="middle">Boon‐bee</forename><surname>Goh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dina</forename><surname>Tiniakos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aileen</forename><surname>Wee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei‐qiang</forename><surname>Leow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jing‐min</forename><surname>Zhao</surname></persName>
			<idno type="ORCID">0000-0003-4345-2149</idno>
		</author>
		<author>
			<persName><forename type="first">Hui‐ying</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao‐xiao</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Qin</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wei‐keat</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kiat‐hon</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Manuel</forename><surname>Romero‐gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Salvatore</forename><surname>Petta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elisabetta</forename><surname>Bugianesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chee‐kiat</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Stephen</forename><forename type="middle">A</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Quentin</forename><forename type="middle">M</forename><surname>Anstee</surname></persName>
			<idno type="ORCID">0000-0002-9518-0088</idno>
		</author>
		<author>
			<persName><forename type="first">Pik‐eu</forename><forename type="middle">Jason</forename><surname>Chang</surname></persName>
			<idno type="ORCID">0000-0002-2702-8412</idno>
		</author>
		<author>
			<persName><forename type="first">Lai</forename><surname>Wei</surname></persName>
			<idno type="ORCID">0000-0001-7519-627X</idno>
		</author>
		<idno type="DOI">10.1002/hep.30986</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<title level="j" type="abbrev">Hepatology</title>
		<idno type="ISSN">0270-9139</idno>
		<idno type="ISSNe">1527-3350</idno>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1953" to="1966" />
			<date type="published" when="2020-05-07">2020</date>
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu F, Goh GB, Tiniakos D et al. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology 2020; 71: 1953-66.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Validation of a machine learning-based approach (DELTA liver fibrosis score) for the assessment of histologic response in patients with advanced fibrosis due to NASH</title>
		<author>
			<persName><forename type="first">A</forename><surname>Taylor-Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pokkalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="949" to="951" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Taylor-Weiner A, Pokkalla H, Han L et al. Validation of a machine learning-based approach (DELTA liver fibrosis score) for the assessment of histologic response in patients with advanced fibrosis due to NASH. Hepatology 2020; 72: 949-51.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study</title>
		<author>
			<persName><forename type="first">Kun</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xue</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hui</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yongyan</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jian</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Minghui</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Changjun</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Changzhu</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Liping</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tian’an</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fankun</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yongping</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hong</forename><surname>Ai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao-Yan</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Li-Ping</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ping</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jie</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rongqin</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.1136/gutjnl-2018-316204</idno>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<title level="j" type="abbrev">Gut</title>
		<idno type="ISSN">0017-5749</idno>
		<idno type="ISSNe">1468-3288</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="729" to="741" />
			<date type="published" when="2019">2019</date>
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang K, Lu X, Zhou H et al. Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut. 2019; 68: 729-41.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Diagnostic accuracy of texture analysis and machine learning for quantification of liver fibrosis in MRI: correlation with MR elastography and histopathology</title>
		<author>
			<persName><forename type="first">Khoschy</forename><surname>Schawkat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alexander</forename><surname>Ciritsis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sophie</forename><surname>Von Ulmenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hanna</forename><surname>Honcharova-Biletska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christoph</forename><surname>Jüngst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Achim</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christoph</forename><surname>Gubler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Joachim</forename><surname>Mertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Caecilia</forename><forename type="middle">S</forename><surname>Reiner</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00330-020-06831-8</idno>
	</analytic>
	<monogr>
		<title level="j">European Radiology</title>
		<title level="j" type="abbrev">Eur Radiol</title>
		<idno type="ISSN">0938-7994</idno>
		<idno type="ISSNe">1432-1084</idno>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="4675" to="4685" />
			<date type="published" when="2020-04-08">2020</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Schawkat K, Ciritsis A, von Ulmenstein S et al. Diagnostic accuracy of texture analysis and machine learning for quantification of liver fibrosis in MRI: correlation with MR elastography and histopathology. Eur. Radiol. 2020; 30: 4675-85.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD</title>
		<author>
			<persName><forename type="first">Takumi</forename><surname>Kawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Katsutoshi</forename><surname>Tokushige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hideyuki</forename><surname>Hyogo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hiroshi</forename><surname>Aikata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tomoaki</forename><surname>Nakajima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Masafumi</forename><surname>Ono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Miwa</forename><surname>Kawanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Koji</forename><surname>Sawada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kento</forename><surname>Imajo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Koichi</forename><surname>Honda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hirokazu</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kohjiroh</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Saiyu</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuya</forename><surname>Seko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuichi</forename><surname>Nozaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yoshihiro</forename><surname>Kamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hideki</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Atsushi</forename><surname>Kawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tetsuo</forename><surname>Takehara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mikio</forename><surname>Yanase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yoshio</forename><surname>Sumida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yuichiro</forename><surname>Eguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Masataka</forename><surname>Seike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Masato</forename><surname>Yoneda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yasuaki</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Toshiji</forename><surname>Saibara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yoshiyasu</forename><surname>Karino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kazuaki</forename><surname>Chayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Etsuko</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Takuji</forename><surname>Torimura</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-018-28650-0</idno>
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<title level="j" type="abbrev">Sci Rep</title>
		<idno type="ISSNe">2045-2322</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">10434</biblScope>
			<date type="published" when="2018-07-11">2018</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Kawaguchi T, Tokushige K, Hyogo H et al. A data mining-based prognostic algorithm for NAFLD-related hepatoma patients: a nationwide study by the Japan Study Group of NAFLD. Sci. Rep. 2018; 8: 10434.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
